JW Life Science said on the 10th that its board of directors approved a cash dividends of 525 won per common share as the settlement of account dividends for the 2025 fiscal year. The dividends aggregates amount to about 8.12939 billion won.
The dividend yield based on the current share price, which is the yield investors receive from dividends, is 4.1%. This was calculated based on the average closing price for the one week before the board resolution date. The record date for dividends is Apr. 1. The dividends will be paid to shareholders within one month after approval at the 32nd annual general meeting of shareholders.
Compared with the previous year, the dividend per share increased by 25 won. JW Life Science's general meeting of shareholders is scheduled for Mar. 26. The dividends decision is planned to be finalized at the annual general meeting of shareholders, and some details may change depending on the external auditor's review, the company said.
Meanwhile, on the 5th, JW Pharmaceutical also held a board meeting and resolved a cash dividends of 500 won per common share. Including a 525 won per-share preferred dividends, the dividends aggregates are 12.1 billion won. In 2024, the dividend per share was 450 won, and the dividends aggregates were 11.1 billion won.
JW Pharmaceutical and JW Life Science are core operating affiliates of JW Holdings. JW Life Science specializes in producing infusion solutions, and JW Pharmaceutical conducts pharmaceutical research and development and sells prescription and over-the-counter drugs. JW Pharmaceutical also sells the infusion solutions developed by JW Life Science.